Gastrointestinal Langerhans cell histiocytosis responding to cladribine and imatinib mesylate

Gastrointestinal involvement in Langerhans cells histiocytosis (LCH) is extremely rare. An optimal treatment regimen is not defined yet and its prognosis is relatively poor. Cladribine, and more recently, Imatinib mesylate (IM) have been recommended as treatment options in refractory LCH. Here we pr...

Full description

Bibliographic Details
Main Authors: Agreda Vásquez, Gladys Patricia, Popoca Barriga, Ulises, Oviedo, Edgar, Lome Maldonado, Carmen, Sánchez Guerrero, Sergio Arturo
Format: Article
Language:English
Published: UANL Facultad de Medicina 2010
Online Access:http://eprints.uanl.mx/8449/1/Gastrointestinal%20Langerhans.pdf
Description
Summary:Gastrointestinal involvement in Langerhans cells histiocytosis (LCH) is extremely rare. An optimal treatment regimen is not defined yet and its prognosis is relatively poor. Cladribine, and more recently, Imatinib mesylate (IM) have been recommended as treatment options in refractory LCH. Here we present a case of gastrointestinal involvement in an adult patient with LCH refractory to several treatment regimens who responded nicely to cladribine and currently treated with IM 300 mg/day, as maintenance, for the last 24 months.